about
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeMAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway.Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanomaDownregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.miR-579-3p controls melanoma progression and resistance to target therapy.Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.Targeting protein kinase-b3 (akt3) signaling in melanoma.MicroRNAs in melanoma development and resistance to target therapy.Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells.Xenotransplantation of pediatric low grade gliomas confirms the enrichment of BRAF V600E mutation and preservation of CDKN2A deletion in a novel orthotopic xenograft mouse model of progressive pleomorphic xanthoastrocytoma.Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.New role of ID3 in melanoma adaptive drug-resistance.The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells.ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.Comparing the genomes of cutaneous melanoma tumors to commercially available cell lines.Game of isoforms: PI3K β-sparing inhibitor is coming.
P2860
Q27853295-6AF1131D-CBA9-4F83-99D3-9E60D9D55FE1Q33566681-6053CACF-1A6A-4998-BB94-417D717E136CQ35597799-AD4E4C04-CB11-4278-9AB3-AE8645A1E5D5Q35665565-AB5DD75D-2008-46E2-B9F5-1BC6160C54ECQ36115818-603AD8AA-E0D9-46DD-B8E0-F53CEE859BC5Q36377576-1B3F78CC-0C80-4658-B214-07AAE383674BQ36682132-A47BC5CE-E47D-41B3-B227-982A756C365CQ37213837-04A68262-C1A2-4EB6-A9DD-38962FA057FAQ38702479-059D1858-8CB5-4812-B19D-D4DC90CD9858Q38842819-A7D5B5BB-F828-41B8-911F-00F9DD40E7C5Q38872439-36D050E7-CEDF-46BB-B06F-2A1BAF8254E7Q38903238-81522225-BA60-4DF1-BE68-C1249FC86C2CQ38951511-443F8BD9-AB6D-4162-9F15-689814E3BC45Q39074281-67DE67FD-A56E-47D8-8F6C-C12AF4A9BDCBQ39101272-5643FE7D-2A6B-468D-9EAF-3F30CA4684D6Q42370484-0D284DFF-7AAD-44C1-9758-7F0A9F82D929Q45750451-6C1A9E60-C3BC-4EDA-9FA6-A99FCE6B8C7FQ46721978-A8611B9D-A534-4BCB-9B75-C34536D05354Q47138762-503B5DAB-BAAA-409D-BC64-9101333BF82FQ47139368-26721D44-F1E6-4F30-BB89-9D30AEC82ADAQ47203970-427DCF39-ADD0-4138-B46A-71B94F49116BQ47554543-06AF435A-ECE7-4EC4-8AED-DFB77EA0267AQ55068792-9A8C4D5F-272D-42E9-B3C6-643D1909CF39
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adaptive resistance to RAF inhibitors in melanoma.
@en
type
label
Adaptive resistance to RAF inhibitors in melanoma.
@en
prefLabel
Adaptive resistance to RAF inhibitors in melanoma.
@en
P2860
P356
P1476
Adaptive resistance to RAF inhibitors in melanoma.
@en
P2093
Andrew E Aplin
Curtis H Kugel
P2860
P304
P356
10.1111/PCMR.12264
P577
2014-06-06T00:00:00Z